cemiplimab + S095024

Cemiplimab + S095024 is a combination therapy consisting of cemiplimab, an anti-PD-1 monoclonal antibody (marketed as Libtayo), and S095024, an investigational anti-CD73 monoclonal antibody. This combination is being studied primarily for advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. - **Cemiplimab** blocks the PD-1 immune checkpoint, thereby boosting T-cell mediated immune responses against tumor cells. - **S095024** inhibits CD73, an ectonucleotidase on the tumor cell surface that generates immunosuppressive adenosine in the tumor microenvironment, helping restore anti-tumor immunity. The combination aims to enhance anti-tumor immune responses beyond single-agent checkpoint blockade, specifically in populations where immune suppression via adenosine (CD73 pathway) is relevant. The drugs are administered intravenously as part of clinical trial protocols, primarily in Phase 1b/2 development for NSCLC[1][2][3][4][8].

Brand names

Libtayo

Other names

anti-PD-1 antibody + anti-CD73 antibody